Understanding Nanoparticle Uptake Mechanisms in Human Corneal Epithelial Cells

Study Background and Research Question

Ocular diseases remain a significant clinical challenge, with topical drug formulations dominating the therapeutic landscape due to their convenience and direct application to the eye. However, these formulations are limited by low bioavailability arising from rapid clearance and formidable ocular surface barriers, particularly the tear film and cornea. The corneal epithelium, constituting merely 10% of the corneal thickness, is responsible for approximately 90% of the barrier function, tightly regulating the passage of substances into the eye. Recent advances in nanotechnology have enabled the development of nanoparticle-based drug delivery systems, which promise to overcome these barriers by improving precorneal retention, tissue penetration, and controlled drug release. Despite extensive research, a critical knowledge gap persists: how do the physicochemical properties of nanoparticles—specifically size and surface chemistry—govern their interactions with and uptake by human corneal epithelial cells (HCECs)? The study by Azadi and David (ACS Biomater. Sci. Eng. 2024) addresses this question through a systematic evaluation of polymeric nanoparticles in an in vitro HCEC model.

Key Innovation from the Reference Study

The principal innovation of the reference study lies in its comprehensive analysis of how nanoparticle size and surface modifications affect cellular uptake mechanisms in HCECs. By synthesizing monodisperse PLGA-based nanoparticles with distinct mucoadhesive (alginate and chitosan) and mucopenetrative (polyethylene glycol, PEG) surface coatings, the authors created a platform to dissect the endocytic pathways responsible for nanoparticle internalization. Notably, the investigation integrates both quantitative uptake analysis and pharmacological inhibition of specific endocytic routes, providing mechanistic clarity that informs the rational design of ocular drug delivery carriers.

Methods and Experimental Design Insights

The study employed an emulsion-solvent evaporation technique to generate spherical PLGA nanoparticles with tight size distributions (100–250 nm; PDI <0.2) and zeta potentials ranging from −25 to +15 mV, depending on the surface polymer. Surface modifications included alginate and chitosan for mucoadhesion, as well as PEG for mucopenetration. Nanoparticle cytotoxicity was assessed via the MTT assay, showing minimal toxicity up to 100 μg/mL after 24 hours of incubation. Cellular uptake experiments were conducted using a well-validated in vitro HCEC monolayer, integrated with simulated mucosal solution to more closely mimic the ocular surface environment. Uptake pathways were further probed using pharmacological inhibitors targeting macropinocytosis, caveolae-mediated endocytosis, and clathrin-mediated endocytosis, while phagocytosis was also evaluated but found not to be significant within the tested size and surface chemistry ranges.

Core Findings and Why They Matter

Quantitative analysis revealed that energy-dependent endocytosis is the primary mode of nanoparticle uptake in HCECs. Among the tested particles, 100 nm PLGA nanoparticles and PEGylated PLGA (PEG-PLGA-150) nanoparticles demonstrated the highest uptake efficiencies. Inhibition studies indicated that macropinocytosis and caveolae-mediated endocytosis are the dominant internalization pathways, with clathrin-mediated endocytosis playing a lesser but measurable role. Notably, phagocytosis was excluded as a significant contributor under the experimental conditions. These results have important implications: by tailoring nanoparticle size (~100–150 nm) and surface chemistry (favoring PEGylation for mucopenetration), it is possible to maximize cellular uptake and, potentially, therapeutic efficacy for ocular drug delivery applications. This mechanistic insight enables informed optimization of nanoparticle formulations, aiming for enhanced corneal penetration, reduced ocular irritation, and improved drug residence time (reference study).

Comparison with Existing Internal Articles

Several recent works corroborate and expand upon these findings. For example, 'Nanoparticle Uptake Pathways in Human Corneal Epithelial Cells' and 'Nanoparticle Uptake in Corneal Cells: Role of Physicochemical Properties' both highlight the importance of nanoparticle size and surface features in dictating cellular uptake, identifying energy-dependent endocytosis—particularly macropinocytosis and caveolae-mediated uptake—as dominant mechanisms. These studies provide actionable design parameters for nanoparticle-based ocular therapeutics, echoing the reference study’s emphasis on mechanistic optimization. Furthermore, 'Nanoparticle Uptake in Corneal Cells: Size and Surface Effects' offers complementary mechanistic insight, focusing on the translation of these findings into safer and more effective ocular drug delivery strategies. Together, these works form a coherent body of evidence guiding the rational engineering of nanoparticles for ophthalmic use.

Limitations and Transferability

While the reference study’s in vitro HCEC monolayer model with simulated mucosal solution provides a robust platform for dissecting uptake mechanisms, several limitations should be acknowledged. First, in vitro models cannot fully recapitulate the dynamic, multilayered architecture and physiological clearance mechanisms present in vivo. The diversity of human corneal cell subtypes and the influence of tear turnover, blinking, and immune factors may impact nanoparticle interactions in the clinical setting. Additionally, only specific size and surface chemistries were evaluated, and the long-term fate of internalized nanoparticles was not addressed. Thus, while the mechanistic findings are highly informative for preclinical design, further in vivo studies are required for validation and translation to clinical practice.

Protocol Parameters

• Nanoparticle synthesis: Use emulsion-solvent evaporation for PLGA nanoparticles, targeting a monodisperse size range of 100–250 nm and PDI below 0.2 for optimal uptake.
• Surface modification: Employ alginate or chitosan for mucoadhesion and PEG for mucopenetrative properties; adjust zeta potential within −25 to +15 mV.
• Cell culture model: Establish a confluent HCEC monolayer and integrate with simulated mucosal solution to mimic the ocular surface.
• Cytotoxicity screening: Conduct MTT assay at nanoparticle concentrations up to 100 μg/mL for 24 h to confirm cell viability (target ≥70%).
• Uptake mechanism validation: Apply specific pharmacological inhibitors to differentiate between macropinocytosis, caveolae-mediated, and clathrin-mediated endocytosis.
• Data analysis: Quantify uptake efficiency and relate to nanoparticle physicochemical properties for mechanistic interpretation.

Research Support Resources

To experimentally dissect cellular uptake pathways, researchers often employ actin polymerization inhibitors to differentiate endocytic mechanisms. Cytochalasin D (SKU B6645) from APExBIO is a potent and selective inhibitor of actin polymerization, widely used to probe the role of actin-dependent processes such as macropinocytosis and phagocytosis. For studies paralleling the referenced work, Cytochalasin D can be applied at concentrations of 0.2–0.5 μg/mL in cell culture to inhibit actin-dependent uptake pathways and clarify mechanistic contributions. Researchers are advised to consult detailed product protocols and adjust parameters according to cell type and application requirements.